share_log

盘中速览 | 三大指数高开低走,内房股、物管股爆发,碧桂园、龙湖涨超8%

Intraday quick overview | The three major indices opened high and fell, domestic housing stocks and property management stocks exploded, and Country Garden and Longhu rose more than 8%

Futu News ·  Nov 24, 2022 11:28

Futu News on November 24, the three major indexes of Hong Kong stocks opened high and fell low, now rising and falling. As of press release, the Hang Seng Index rose slightly, while the Hang Seng Index fell slightly.

The rise and fall of science and technology stocks are mixed.Kuaishou Technology and NetEase, Inc rose by more than 1%, XIAOMI fell by more than 4%, and Tencent, Meituan and BABA fell slightly.

Inner housing stocks and property management stocks soared.Country Garden Holdings and Longhu rose by more than 8%, and Sunac Services by more than 12%.

Gold stocks strengthenShandong Gold Mining rose by more than 4%, Zhaojin Mining and Zijin Mining Group by about 3%.

Partial pullback of central enterprises and infrastructure sectorsChinalco International fell more than 15%, China Communications Construction fell nearly 4%, China Metallurgical, China Railway Construction Corporation and others followed suit.

The anti-epidemic plate is higher.Clover organisms rose by more than 16%, while CSPC Pharmaceutical and CANSINOBIO rose by about 2%.

Individual stocks$LONGFOR GROUP (00960.HK)$An increase of more than 8%, the monarch said that the company is expected to be revalued under the "Financial Article 16", and the "second Arrow" will expand the company's initial 2 billion votes.

$Smoore International Holdings Limited (06969.HK)$It rose by more than 2%. Yesterday, the two departments issued a circular on the limited management of sending and delivering e-cigarette products, atomization, nicotine for e-cigarettes, and so on.

$XIAOMI-W (01810.HK)$Revenue fell more than 4% in the third quarter from a year earlier to 70.474 billion yuan, while smartphone revenue fell 11.1% to 42.5 billion yuan.

$ASCLETIS-B (01672.HK)$Increased nearly 2%, COVID-19 oral drug 3CLpro inhibitor ASC11 new drug clinical trial application was approved by the FDA of the United States.

Edit / new

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment